Lindsell Train Ltd Acquires Shares of 407,240 Thermo Fisher Scientific Inc. (NYSE:TMO)

Lindsell Train Ltd bought a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) during the 4th quarter, HoldingsChannel reports. The fund bought 407,240 shares of the medical research company’s stock, valued at approximately $211,858,000. Thermo Fisher Scientific makes up approximately 5.3% of Lindsell Train Ltd’s portfolio, making the stock its 9th largest holding.

Several other institutional investors and hedge funds also recently made changes to their positions in TMO. Legacy Investment Solutions LLC purchased a new position in shares of Thermo Fisher Scientific in the third quarter worth $26,000. Peterson Financial Group Inc. bought a new stake in Thermo Fisher Scientific in the 3rd quarter worth about $27,000. Missouri Trust & Investment Co bought a new position in Thermo Fisher Scientific during the 4th quarter valued at about $29,000. Endeavor Private Wealth Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at about $30,000. Finally, Decker Retirement Planning Inc. bought a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $43,000. Institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. TD Cowen raised their target price on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a report on Tuesday, October 22nd. Stifel Nicolaus cut their price objective on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a report on Thursday, October 24th. Evercore ISI lowered their target price on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. StockNews.com upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Finally, Scotiabank assumed coverage on shares of Thermo Fisher Scientific in a report on Monday, December 23rd. They issued a “sector perform” rating and a $605.00 price objective on the stock. Four analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $648.95.

Thermo Fisher Scientific Trading Up 0.0 %

Thermo Fisher Scientific stock opened at $574.83 on Friday. The stock has a market cap of $219.87 billion, a P/E ratio of 36.04, a PEG ratio of 3.82 and a beta of 0.76. The firm’s 50 day moving average price is $531.52 and its 200-day moving average price is $569.01. Thermo Fisher Scientific Inc. has a 1 year low of $493.30 and a 1 year high of $627.88. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. The firm had revenue of $10.60 billion during the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The business’s quarterly revenue was up .2% compared to the same quarter last year. During the same quarter last year, the business posted $5.69 earnings per share. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date of this dividend was Friday, December 13th. Thermo Fisher Scientific’s payout ratio is 9.78%.

Thermo Fisher Scientific announced that its board has initiated a stock repurchase plan on Friday, November 15th that authorizes the company to repurchase $4.00 billion in shares. This repurchase authorization authorizes the medical research company to purchase up to 2% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its shares are undervalued.

Insider Activity

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $558.12, for a total value of $5,581,200.00. Following the completion of the transaction, the chief executive officer now owns 33,608 shares of the company’s stock, valued at approximately $18,757,296.96. This trade represents a 22.93 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders sold 44,850 shares of company stock worth $24,666,097. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.